Amundi
KRYS icon

Amundi’s Krystal Biotech KRYS Stock Holding History

Amundi’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62M Sell
4,368
-1,338
-23% -$400K ﹤0.01% 1235
2026
Q1 		$1.47M Buy
5,706
+1,952
+52% +$519K ﹤0.01% 1176
2025
Q4 		$926K Sell
3,754
-807
-18% -$170K ﹤0.01% 1289
2025
Q3 		$824K Buy
4,561
+367
+9% +$54.9K ﹤0.01% 1203
2025
Q2 		$593K Buy
+4,194
New +$616K ﹤0.01% 1330
2022
Q4 		– Sell
-1,762
Closed -$123K – 1943
2022
Q3 		$123K Hold
1,762
– – ﹤0.01% 1526
2022
Q2 		$126K Buy
+1,762
New +$110K ﹤0.01% 1415

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Amundi's KRYS Position: Q2 2026 in Review

Amundi reduced its Krystal Biotech (KRYS) stake by 23% in Q2 2026, selling an estimated $400K and leaving 4,368 shares worth $1.62M. The position accounts for ﹤0.01% of the portfolio, ranked #1235.

Amundi first reported a position in KRYS in Q2 2022 and has held it in 7 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Amundi held 4,368 shares of Krystal Biotech worth $1.62M as of Q2 2026.
  • Amundi sold 1,338 Krystal Biotech shares in Q2 2026, an estimated $400K.
  • Krystal Biotech made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1235 holding.
  • Amundi first reported a position in Krystal Biotech in Q2 2022 and has held it in 7 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.